NDAORALSUSPENSION
Approved
Dec 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
INDERAL (propranolol hydrochloride) by Thayer Medical is clinical pharmacology general propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. First approved in 1986.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INDERAL (propranolol hydrochloride) is a nonselective beta-adrenergic receptor blocker used to treat hypertension, angina pectoris, arrhythmias, and migraine prophylaxis. It works by competing with beta-adrenergic stimulants for receptor sites, reducing heart rate, cardiac contractility, and blood pressure, while at higher doses exerting membrane-stabilizing effects similar to quinidine.
LOE Approaching
As a legacy product approaching loss of exclusivity with modest competitive pressure (30%), commercial teams face contraction risk and focus will shift toward managed care access and cost-containment strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY General Propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic receptor-stimulating agents for available receptor sites. When access to beta-receptor sites is…
Worked on INDERAL at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.